EMA/351214/2023

# European Medicines Agency decision

P/0378/2023

of 8 September 2023

on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (Ajovy), (EMEA-001877-PIP01-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0378/2023

of 8 September 2023

on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (Ajovy), (EMEA-001877-PIP01-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0301/2016 issued on 4 November 2016, the decision P/0308/2017 issued 31 October 2017 and the decision P/0411/2019 issued on 04 December 2019,

Having regard to the application submitted by Teva GmbH on 24 April 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for fremanezumab (Ajovy), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to Teva GmbH, Graf-Arco-Str. 3, 89079 – Ulm, Germany.

EMA/PDCO/202541/2023
Amsterdam, 21 July 2023

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001877-PIP01-15-M04

## Scope of the application

**Active substance(s):**

Fremanezumab

**Invented name:**

See Annex II

**Condition(s):**

Prevention of migraine headaches

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

Teva GmbH

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Teva GmbH submitted to the European Medicines Agency on 24 April 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0301/2016 issued on 4 November 2016, the decision P/0308/2017 issued 31 October 2017 and the decision P/0411/2019 issued on 04 December 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 22 May 2023.

## Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

# 1. Waiver

## *1.1. Condition*

Prevention of migraine headaches

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

# 2. Paediatric investigation plan

## *2.1. Condition*

Prevention of migraine headaches

### 2.1.1. Indication(s) targeted by the PIP

Prophylaxis of headache in children aged 6 years to less than 18 years with episodic and chronic migraine

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Solution for injection

### 2.1.4. Measures

| Area | Description |
|---|---|
| Quality-related studies | - |
| Non-clinical studies | **Study 1**<br>Reproductive toxicity and post-natal development study.<br>**Study 2**<br>Definitive juvenile toxicity study. |
| Clinical studies | **Study 3**<br>Pharmacokinetic and safety study in paediatric patients from 6 years to less than 12 years of age following a single subcutaneous dose of fremanezumab (TV48125-CNS-10141). |

| | |
|---|---|
| | **Study 4**<br><br>Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with episodic migraine (EM) (TV48125-CNS-30083).<br><br>**Study 5**<br><br>Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with Chronic Migraine (CM) (TV48125-CNS-30082).<br><br>**Study 6**<br><br>Long-term, safety, tolerability and efficacy open-label single arm study of fremanezumab in paediatric patients from 6 years to less than 18 years of age with history of migraine (CM or EM) who participated to Study 4 and 5 (TV48125-CNS-30084). |
| Extrapolation, modelling and simulation studies | **Study 7**<br><br>Modelling and simulation dose-finding study based on a one-compartment model with allometric weight scaling with data from adult healthy volunteers and patients with EM and CM (CP-18-03).<br><br>**Study 8**<br><br>Modelling and simulation dose-finding study based on a two-compartment model with allometric weight scaling with data from paediatric pharmacokinetic study 3 (CP-18-05).<br><br>**Study 9**<br><br>Modelling and simulation inferential study including a comprehensive evaluation of the effect of covariates on PK and exposure-response parameters pooling all available paediatric and adult data. |
| Other studies | Not applicable. |
| Other measures | Not applicable. |

# 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By December 2027 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

***Information provided by the applicant:***

## Condition(s) and authorised indication(s)

1. Prevention of migraine headaches

Authorised indication(s):

- Prophylaxis of migraine in adults who have at least 4 migraine days per month
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous use
  - Authorised via centralised procedure